Home＞BUSINESS
Mochida to Market Janssen’s Anticancer Agent Doxil in Japan(Nov.22.2017)
Mochida Pharmaceutical said on November 20 that it has entered into an agreement with Janssen Pharmaceutical for the marketing of the partner’s anticancer agent Doxil Injection 20 mg (doxorubicin) in Japan. Under the pact, Mochida will be responsible for the information provisioning to medical institutions and the distribution of the product from January 2018 ...
(LOG IN FOR FULL STORY)
-
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected Apr.20
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers Apr.20
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup Apr.19
- Astellas Sells Agensys Research Facilities to Kite Apr.19
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit Apr.19
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President(Apr.19)
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official(Apr.19)
